Last reviewed · How we verify
Trecator (ETHIONAMIDE)
Trecator (ETHIONAMIDE) is a small molecule antimycobacterial drug originally developed by WYETH PHARMS INC and currently owned by Wyeth Pharms. It was FDA approved in 1965 for the treatment of acute tuberculosis, pulmonary Mycobacterium avium complex infection, and pulmonary tuberculosis. Trecator is off-patent and has no active Orange Book patents, indicating it is available as a generic medication. However, there are currently no generic manufacturers listed. As an off-patent medication, its commercial status is subject to change.
At a glance
| Generic name | ETHIONAMIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antimycobacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Acute tuberculosis
- Pulmonary Mycobacterium avium complex infection
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- PanACEA - STEP2C -01 (PHASE2)
- A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098 (PHASE2)
- Triage Test for All Oral DR-TB Regimen (TRiAD Study)
- A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide (PHASE2)
- An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (PHASE2)
- TB-CAPT MTB/XDR Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |